Azienda Ospedaliera Di Perugia — Clinical Trial Site

45 Registered trials

24 Currently recruiting

Organisation

Azienda Ospedaliera Di Perugia

Location

Perugia, Italy

Identifier

ORG-100030934

Address

Via Gerardo Dottori 1, 06132, Italy

Departments

138006: Ematologia
4106:SC Oncologia Medica
Cardiology and Cardiovascular Pathophysiology Unit
Centro Ricerche Emato-oncologiche
Department of Medicai Oncology
Department of medical oncology
Dipartimento di Oncologia Medica
Divisione di Ematologia
Ematologia
Internal Medicine
IT040A: SC Ematologia e Trapianto Midollo Osseo
Medical Oncology
Medicine & Surgery
Medicine and Surgery Department
Oculistica
Oncologia
Oncologia Medica
Oncology
Rhumatology
S. C. Medicina Interna
S. C. Oncologia Medica
S.C. Cardiologia
S.C. Clinica Neurologica
S.C. di Endocrinologia e Malattie Metaboliche
S.C. Oncologia Medica
S.C. Pneumologia
SC di Endocrinologia e Malattie Metaboliche
SC Ematologia - Trapianto di Midollo Osseo
SC Geriatria
SC Oncologia Medica
SC Oncologia Medica - Dip. Scienze Onco-Emato-Gastroenterologiche
Stroke Unit
Struttura Complessa Medicina Interna
Unità di Dermatologia
UO Oncologia Medica
UOC Chirurgia dell'Apparato Digerente
UOC di Oncologia Medica

Clinical trials at this site (45)

Search interface

A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima… Recruiting

2024-518893-15-00 Chronic lymphotic leukemia and Small Lymphocytic lympho 5 2025-07-29
Randomized phase II trial of Cemiplimab plus OSE2101 (TEDOPI®) as maintenance therapy in ctDNA positive NSCLC. Recruiting

2024-519262-42-00 NSCLC non-small cell lung cancer 4 2025-07-15
A phase 2A pilot study to assess the safety and efficacy of eltanexor in relapsed/refractory NPM1-mutated acute myeloid leukemia Recruiting

2024-514724-16-01 Acute Myeloid Leukemia 4 2025-01-14
A Phase 1/2 study of Enzomenib (DSP-5336) in Adult Patients with Acute leukemia Recruiting

2022-502741-10-00 Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearra 7 2024-01-26
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting

2022-500587-35-01 Stroke 5 2023-07-06
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: … Recruiting

2024-515981-14-00 Gastric adenocarcinoma with peritoneal metastases 5 2022-12-14
Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting

2023-508852-21-00 Resectable, Early-stage (II to IIIB) Non-small Cell Lun 4 2022-06-10
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study Ended

2024-512180-31-00 Oligometastatic renal cell carcinoma 4 2025-03-14
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Ended

2023-509408-13-00 Solid tumors 6 2022-09-20
New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients Ended

2023-510054-16-00 Primary Sjogren's syndrome 4 2022-04-26
Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch… Ended

2022-502354-14-00 Completely resected Stage IIb/c melanoma 5 2019-10-28
Study with investigational drug PF-06463922 and comparator crizotinib in patients with a specific type of advanced lung cancer Ended

2023-509169-19-00 Advanced ALK positive non-small cell lung cancer 5 2017-07-11
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended

2025-521107-42-00 Alzheimer's Disease 4 2025-11-25
Extension study to evaluate the long-term outcomes of subjects in study 20090 Ended

2023-504207-89-00 Retinopathy of prematurity 5 2020-03-27
A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended

2022-502886-71-00 Previously Untreated Locally Advanced Non-small Cell Lu 5 2019-11-20
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung… Ended

2022-501360-18-00 Early Stage Non-Small Cell Lung Cancer (NSCLC) 5 2017-03-15
Multicenter trial with carfilzomib combined with lenalidomide or cyclophopshamide with or without autologous transplant in newly diagnosed m… Ended

2024-516630-35-01 NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE 4 2015-01-12